Back to Journals » International Journal of Women's Health » Volume 8

Sildenafil citrate for the management of fetal growth restriction and oligohydramnios

Authors Choudhary R, Desai K, Parekh H, Ganla K

Received 12 March 2016

Accepted for publication 26 May 2016

Published 9 August 2016 Volume 2016:8 Pages 367—372

DOI https://doi.org/10.2147/IJWH.S108370

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Fredrick Rosario Joseph

Peer reviewer comments 3

Editor who approved publication: Professor Elie Al-Chaer


Rana Choudhary,1 Kavita Desai,2 Hetal Parekh,3 Kedar Ganla1

1Department of Reproductive Medicine, Ankoor Fertility Clinic, 2Department of Radiology, Dadar Imaging and Diagnostic Centre, 3IVF Department, Hiranandani Hospital, Mumbai, India

Abstract: Fetal growth restriction (FGR) and preeclampsia are the major causes of neonatal morbidity and mortality, which affect up to 8% of all pregnancies. The pathogenesis in FGR is an abnormal trophoblastic invasion leading to compromised uteroplacental circulation. However, in spite of this understanding and identification of high-risk patients, the management options are limited. There are some new studies which have demonstrated the role of sildenafil citrate in improving vasodilatation of small myometrial vessels and therefore improvement in amniotic fluid index, fetal weight, and even uterine and umbilical artery Doppler patterns. We report here the case of a 31-year-old female with infertility and preconceptional thin endometrium responding well to sildenafil citrate, followed by conception. However, she presented with an early-onset FGR at 26 weeks of gestation, and again after treatment with sildenafil citrate, showed improvement in amniotic fluid index and fetal weight, finally resulting in delivery of a full-term healthy baby with uneventful neonatal course.

Keywords: sildenafil citrate, fetal growth restriction, oligohydramnios, thin endometrium

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]